Abstract: The present invention relates to improved epicutaneous administration methods for vaccination of a subject. In particular, the present invention discloses the use of an antigen for epicutaneous immunization, wherein the antigen is administered by epicutaneous application with a skin patch device in combination with an epidermal skin treatment.

Abstract: Provided is a method by which a nucleic acid sample can be collected from a subject minimally invasively. A method for preparing a nucleic acid derived from a skin cell of a subject, comprising isolating the nucleic acid from skin surface lipids collected from the subject.

Abstract: The present invention is directed to a process for manufacturing a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and release liner. More specifically, the invention is directed to a process of preparing an adhesive layer, wherein the adhesive layer is comprised of polyisobutylene and an active pharmaceutical ingredient.

Abstract: The present disclosure provides a patch preparation having features that prevent accidental use. In some embodiments, a patch preparation containing a plaster on a support, wherein the plaster comprises a solvent that is a combination of ethyl acetate and n-heptane. The patch preparation can lose its adhesion after the plaster is exposed to air and at least some of the solvent has evaporated, or if the patch is removed from the skin. This feature prevent the used patch from being applied to the skin again, and can prevent accidental use. A method of forming a patch preparation is also disclosed.

Abstract: Systems, apparatuses, and methods for providing negative pressure to a tissue site are disclosed. Illustrative embodiments may include an apparatus or system for delivering negative-pressure to a tissue site, which can be used in conjunction with low-profile distribution components for wound therapy. Such apparatus may include a low-profile dressing interface or connector comprising at least two fluid pathways fluidly coupled to a recessed space of the connector, one for providing negative pressure to a tissue interface or manifold and the other for sensing the negative pressure within the recessed space adjacent the tissue interface. In some embodiments, a pressure-offloading layer may be disposed against at least one of the fluid pathways.

Abstract: An antimicrobial article that includes: an antimicrobial composite region that includes a matrix comprising a polymeric material, and a first plurality of particles within the matrix. The particles include a phase-separable glass with a copper-containing antimicrobial agent. The antimicrobial composite region can be a film containing the first plurality of particles that is subsequently laminated to a bulk element. The first plurality of particles can also be pressed into the film or a bulk element to define an antimicrobial composite region. An exposed surface portion of the antimicrobial composite region can exhibit at least a log 2 reduction in a concentration of at least one of Staphylococcus aureus, Enterobacter aerogenes, and Pseudomonas aeruginosa bacteria under a Modified EPA Copper Test Protocol.

Abstract: A device for delivery of a therapeutic agent to a surgical cavity, including: a porous, mucoadhesive, freeze-dried polymeric matrix having first and second opposed surfaces, the matrix formed by a composition including chitosan; a plurality of particles embedded within the matrix, the particles containing the therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan. The first surface of the matrix is configured to be applied to the surgical cavity; the device releases the particles through the first surface; the device is also sterilized and provides release of approximately 20% to 100% of the therapeutic agent within 20 minutes of application to the surgical cavity.

Abstract: The present invention relates to an oral dissolvable film (ODF) containing an active ingredient (e.g., vitamin D) that is, outside of the ODF, relatively unstable to at least one of heat, light, moisture, and oxygen. The present invention also relates to methods of manufacturing and using the same.

Abstract: A dispensable grease sealant includes a base component in an amount of 50 wt % or more, based on a total weight of the sealant, and a thickener. The base component is selected from a group including a silicone wax, a liquid rubber, and a combination thereof.

Abstract: A system that transdermally delivers a drug to a patient can be used to reduce suffering from acute/chronical musculoskeletal pain. The system includes a backing layer, an adhesive layer, a topical applicator, a suitable quantity of drug, and a quantity of topical carrier. The topical applicator is connected across and against the backing layer by the adhesive layer. The suitable quantity of drug and the quantity of topical carrier are homogenously mixed together as a topical medication, which is retained and dispensed from the topical applicator. The topical applicator includes a flat applicator body, a plurality of blunted spikes, and a containment rim. The flat applicator body is the structural base of the topical applicator. The containment rim is used to perimetrically confine the topical medication. The blunted spikes are used to increase the surface area of the topical applicator in order to improve its retention of the topical medication.

Abstract: A nitric oxide-releasing 3D printing ink is described for its composition and uses in fabricating a plurality of types of nitric oxide-releasing medical devices. The printing ink composition comprises a mixture of at least one nitric oxide donor and at least one polymer. The nitric oxide-releasing medical device is manufactured by 3D printing technology and provides antimicrobial and/or antithrombus effects by releasing nitric oxide in the presence of moisture.

Abstract: The present invention relates to polyoxazoline polymers, polymer combinations and compositions comprising those polymers or combinations of polymers. The invention further relates to the use of said polyoxazoline polymers, said combinations and compositions comprising such polymers and combinations for the sustained release of one or more active ingredients, in particular one or more active pharmaceutical ingredients. It further relates to the use of polyoxazoline polymers or polymer combinations as drug carrier.

Abstract: An antibacterial polymer and a preparation method thereof are provided. The antibacterial polymer is obtained by polymerization of a polyol and a guanidine salt, and has the following structure: In the preparation method, non-toxic and non-irritating polyols are used as raw materials, wherein the non-toxic and non-irritating polyols are friendly to an environment and a human body.

Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a polymer matrix and one or more flavorants and/or active ingredients embedded in the polymer matrix. The polymer matrix can include a copolymer of ethylene and one or more vinyl monomers or zein. For example, the polymer can be ethylene-vinyl acetate copolymer and/or ethylene-vinyl alcohol copolymer. In some cases, the oral product can include tobacco and/or nicotine.

Abstract: The subject invention provides topical therapeutic compositions and methods of their use for enhanced healing of wounds, including burns, and scars of the skin. Specifically, in one embodiment, the subject invention provides materials and methods for reducing the healing time of skin wounds and for reducing the appearance of scars. The subject invention utilizes topical compositions comprising microbial growth by-products and, optionally, a topically-acceptable carrier. In specific embodiments, the microbial growth by-products are biosurfactants.

Abstract: Compositions and methods for the treatment or prophylaxis of viral and other infections (e.g., coronavirus) are provided. The compositions typically comprise a quinoline derivative and an additional anti-viral agent. Incorporations of these agents into fabrics for use as filtration devices which forestall infection is also disclosed.

Abstract: Separable microneedle arrays and microneedle patches are provided that may achieve sustained release of drug. The microneedle arrays may include one or more features that facilitate separation of the microneedles, such as a bubble structure. The microneedle arrays may include an effervescent material.

Abstract: A wound dressing, suitable for use in negative pressure wound therapy, comprising a body of porous material, the body of porous material comprising a plurality of cuts which provide regions of flexibility within the body. Further embodiments relate to methods of manufacturing and method of use of such wound dressings. In addition, the wound dressing can comprise a retaining mechanism removably coupled to the material and configured to retain the material in the expanded conformation.

Abstract: Embodiments herein relate to cell encapsulation membranes, devices including the same, and related methods. In an embodiment, a cell encapsulation membrane is included. The cell encapsulation membrane can include a mesh substrate. The mesh substrate can include a first series of fibers extending in a first direction and a second series of fibers extending in a second direction, the first series of fibers intersecting with the second series of fibers, the mesh substrate defining a plurality of apertures disposed between adjacent fibers of the first series and the second series. The cell encapsulation membrane can further include a coating disposed on the mesh substrate, the coating partially occluding the plurality of apertures defined by the mesh substrate and forming pores. Other embodiments are also included herein.

Abstract: There is provided a plastic material comprising at least one cannabinoid embedded within a structural polymer, wherein the plastic material is formulated to exude the at least one cannabinoid through an outer surface of the plastic material at a therapeutically effective rate for a period of at least a week or at least a month. The plastic material may comprise a liquid-absorbent material embedded within the structural polymer and a carrier oil absorbed into the liquid-absorbent material, wherein at least one cannabinoid is dissolved in the carrier oil.

Abstract: A composite scaffold having a highly porous interior with increased surface area and void volume is surrounded by a flexible support structure that substantially maintains its three-dimensional shape under tension and provides mechanical reinforcement during repair or reconstruction of soft tissue while simultaneously facilitating regeneration of functional tissue.

Abstract: Water-soluble cleansing wipes or pads comprising a water-soluble support and their uses in the cosmetic field for cleansing of the skin are disclosed.

Abstract: Provided is a microneedle patch comprising a substrate part and multiple needle parts protruding from the substrate part. The substrate part consists of a diffusion-proof layer and a base, and each needle part consists of a needle tip, a diffusion-proof layer and a base. The diffusion-proof layer of each needle part is formed between the needle tip and the base of the corresponding needle part. The diffusion-proof layer of the substrate part and the diffusion-proof layer of needle part are one-piece structures, and so are the base of the substrate part and the base of the needle part. The diffusion-proof layer of the microneedle patch can prevent the active ingredients from diffusing to the base, limit the active ingredients to the needle tip and control the carrying quantity thereof.

Abstract: The present invention pertains to quantum-scale biocidal particles and chemical reactions that disrupt and eviscerate microbial matter by combining aqueous and dry components. As halo-fullerene activation requires volatile excitation to mix, contact and collide so as to rupture microbial matter, atomic scale chemical reactions impart the requisite movement of engineered halo-fullerenes to destroy bacterial, fungal and viral matter upon contact. The present invention includes two primary mechanisms: an excitation chemistry and biocidal, hydrophobic halo-fullerenes. Upon aqueous exposure, the dry composition initiates a chemical reaction that activates biocidal halo-fullerenes to disrupt biologic surfaces in topical applications. The object of the present invention is a shelf stable, pre-packaged wiping material or dry packet for rehydration with broad spectrum antimicrobial activity.

Abstract: The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (?5?1?1), laminin 521 (?5?2?1), or a fragment of these.

Abstract: A transdermal therapeutic system containing rotigotine base in a self-adhesive layer structure. The system includes a backing layer, and a rotigotine-containing biphasic layer. The biphasic layer has an outer phase having a composition including 75% to 100% of a polymer or a polymer mixture, and an inner phase that forms dispersed deposits in the outer phase. The inner phase includes rotigotine base and a polymer mixture of at least two hydrophilic polymers. The hydrophilic polymers are selected from the group of polyvinylpyrrolidones having a K-Value of at least 80, polyvinylpyrrolidones having a K-Value of less than 80, copolymers of vinyl caprolactam, vinylacetate and ethylene glycol, copolymers of vinylpyrrolidone and vinylacetate, copolymers of ethylene and vinylacetate, polyethylene glycols, polypropylene glycols, acrylic polymers, and modified celluloses. The polymer mixture in the inner phase is present in an amount sufficient so that it forms a solid solution with the rotigotine base.

Abstract: The invention relates to a multi-layered fabric comprising an absorption layer between two liquid-permeable layers, which multi-layered fabric has a surface with: 1) one or more connection areas wherein a connection is present between both layers; and 2) one or more absorption areas wherein both layers are not connected to each other. The absorption areas are capable of absorbing a liquid whereby the liquid is absorbed by the absorption layer. The connection between the layer L1 and the layer L2 comprises a fusion of the layer L1 and the layer L2, which fusion optionally also includes the absorption layer.

Abstract: Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive log P. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.

Abstract: A medical polymer device comprising a biodegradable polymer is provided, wherein the biodegradable polymer has a crystallinity of about 10% to about 80%, and preferably from about 20% to about 60%, wherein the medical polymer device comprises a small molecule organic compound which diffuses into the biodegradable polymer, the small molecule organic compound has a molecular weight of from about 100 to about 1000 Daltons, preferably from about 150 to about 500 Daltons, and more preferably from about 150 to about 250 Daltons, and the small molecule organic compound is non-evaporating or low-evaporating. The present invention also provides a method for preparing a medical polymer device according to the present invention as well as a method for modifying a medical polymer device made from a biodegradable polymer.

Abstract: An object of the present invention is to provide an asenapine-containing patch having excellent sustained-release properties while enhancing skin permeability by using a silicone-based pressure-sensitive adhesive base. The present invention relates to a patch having a support and a pressure-sensitive adhesive layer, wherein the pressure-sensitive adhesive layer comprises asenapine and/or a pharmaceutically acceptable salt thereof, a silicone-based pressure-sensitive adhesive base and a release control agent, and the ratio of the maximum skin permeation rate of asenapine to the minimum skin permeation rate from the time when the maximum skin permeation rate is reached to 24 hours is less than 1.62.

Abstract: A method, material, and kit for promoting neutrophils and monocytes to localize at a chronic ulcer site, promoting formation of a multi-layered cell structure in the ulcer site, promoting conversion of monocytes to macrophages, promoting secretion of the patient's own growth factors, promoting tissue proliferation and cell migration, promoting production and cross-linking of collagen at the chronic ulcer site, promoting growth of endothelial cells, promoting angiogenesis that was stalled at the chronic ulcer site, promoting formation of a vascular network and granulation, promoting oxygenation of the chronic ulcer site, and reducing one or more of purulent drainage, erythema, pain, warming, tenderness, induration, and bleeding at the chronic ulcer site.

Abstract: A biocompatible membrane comprised of alginate and hyaluronate. The membrane may be used to prevent unwanted scarring after surgery. The tissue adherence and the rate of bioresorption of the membrane may be modified through an external stimulus comprising a sequestering agent and a viscosity modifier.

Abstract: An implant for treating a bone defect wherein the implant comprises osteoconductive supporting bodies and an insertion aid. The insertion aid is designed for insertion of the osteoconductive supporting bodies into a bone defect and for holding together the osteoconductive supporting bodies. Also disclosed is a kit comprised of an implant for treating a bone defect.

Abstract: A method for preparing a conductive biomimetic skin scaffold material with self-repairing function includes the following steps: adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to a homogeneous dispersion of acidified carbon nanotubes, poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS), and gelatin to cross-link to obtain a conductive composite colloid; and injecting the conductive composite colloid into a mold, aging at ?4-4° C. for 12-24 hours, and then soaking in a phosphate-buffered saline (PBS) solution with a pH of 7.0-7.4 for 12-24 hours to obtain the conductive biomimetic skin scaffold material.

Abstract: Described are methods, compositions, and devices for a concatemeric protein standard that behaves as a protein but transforms into single peptides upon digestion, which is optimized to function as a non-obtrusive process control for mass spectrometry analysis.

Abstract: Thermally stable absorbable fiber populations, i.e. fiber populations that do not undergo thermally induced crystallization, can be intermixed with thermally unstable fibers to yield a stabilizing effect without altering morphological properties of a fiber system. Via this, one may minimize thermally induced shrinkage and maintain physical properties of electrospun materials in the as-formed state.

Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.

Abstract: Improved methods and compositions are disclosed for treating dry eye by administering intranasally a therapeutically effective amount of a capsaicinoid compound embedded in multiple layers of solid lamellar crystals of monoglycerides to patients with deficient tear production. The lipophilic capsaicinoid drug is embedded in multiple layers of solid lamellar crystals of monoglycerides, and these crystals are incorporated into pharmaceutically acceptable vehicles comprised of solutions, suspensions, foams, creams, ointments, and gels. The resulting formulations of the capsaicinoid are suitable for application to the nasal mucosa or skin and are more stable, less irritating to skin and mucous membranes, and provide increased and more controlled release of the capsaicinoid compound.

Abstract: A dressing for treating a tissue site with negative pressure includes a manifold having a first surface and a second surface opposite the first surface. The dressing also includes a first layer adjacent to the first surface and a second layer adjacent to the second surface. The first layer and the second layer each include a polymer film. The dressing also includes a plurality of fluid restrictions in the polymer film adjacent to at least the first surface, and a plurality of bonds between the first layer and the second layer. The plurality of bonds defines separable sections of the manifold.

Abstract: Absorbent materials configured to sequester trimethylamine (TMA), absorbent articles made therefrom, related methods of use, methods of measuring a reduction of free TMA, and related methods of making absorbent articles are described.

Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm.

Abstract: Orodispersible films (ODFs) and methods for making the same.

Abstract: An antibacterial leather uses the organic silica gel as the main component, uses the carboxymethyl chitosan silver as the antibacterial factor, and uses the modified nano-silica and the modified layered double oxide as the flame retardant factor. The synergistic effects between the components, such as the good binding between carboxymethyl chitosan silver and the substrate, the synergistic flame retardant effect between flame retardant factors, the bonding effect between modified nano-silica and dimethicone, and the synergistic effect between the high-viscosity dimethicone and the low-viscosity dimethicone are utilized to improve the process, thereby obtaining a good antibacterial, flame retardant and other properties, meanwhile meeting the requirement for the material mechanical properties and environmental protection.

Abstract: The invention provides fabrics that incorporate protease enzymes that inactivate viruses and bacteria. The fabrics of the invention may be used in the production of various items of self-sterilizing protective equipment including protective facemasks.

Abstract: Compositions and methods for skincare treatment are provided. The invention relates more generally to skin care treatment and more particularly, to compositions and methods for promoting healthy skin, skin regeneration, skin repair, skin bed preparation, and enhanced wound healing.

Abstract: A compostable biopolymer adhesive may include a starch, a hydroxylic liquid, a preservative mixture, a crystallization inhibitor, and a carbonate, wherein the compostable biopolymer may be free of synthetic materials yet has a long shelf life, is stable at room temperature, and which can be used to make slime for play. The preservative mixture may include a mixture of saccharides and salt, and the salt may make up about 10 to about 90 wt. % of the dry materials used to make the compostable biopolymer adhesive.

Abstract: A device or system includes a mixer comprising a three-dimensional lattice defining a plurality of tortuous, interconnecting passages therethrough. The mixer is in communication with sources or streams of at least two separate components which, when mixed, form a combined fluid stream. The sources or streams may be, at least initially, on opposite sides of the mixer, or the sources or streams may be on the upstream side of the mixer with an outlet disposed downstream of the mixer. A related method may include providing a mixer comprising a three-dimensional lattice defining a plurality of tortuous, interconnecting passages therethrough, and selecting a material for the mixer based on physical characteristics of said material, said characteristics including a selected one or more of mean flow pore size, thickness and porosity volume.

Abstract: Compositions for treatment of cystinosis, products for administering eye drops, and products for storing contact lenses are provided. Compositions include solutions that can contain an effective amount of cysteamine to treat cystinosis, and an oil with a lower density than the solution. Also provided is a product including a bottle for containing a solution, the bottle being substantially free of O2. Also provided is a contact lens holder for storing one or more contact lenses in a solution, the holder including barrier layers reducing the amount of O2 entering the contact lens holder.

Abstract: A method for making an improved contact lens with the steps of providing a mold with a space between the top surface and a bottom surface, and positioning a mat in the space of the mold, providing a bead of liquid polymer of predetermined size at a predetermined location on the surface of the mat, pressing the bead of liquid polymer into the mat between the top surface and the bottom surface of the mold to form an optical zone framed by a mat peripheral zone, exposing the optical zone and the peripheral zone with U-V radiation to harden the optical zone into a composite improved contact lens, removing the cross-linked improved contact lens from the mold, processing the peripheral zone surrounding the optical zone to have a fenestration surface having holes, the holes being through holes with predetermined diameters selected to pass larger proteins, lipids, metabolites.

Abstract: An ostomy barrier includes an inlet opening for receiving a stoma and a barrier adhesive including a plurality of thicker portions and a plurality of thinner portions. The plurality of thinner portions are configured and arranged to improve the flexibility of the ostomy barrier.